VIDPREVTYN Beta, a new COVID-19 vaccine developed by Sanofi, has been authorised by the UK Medicines and Healthcare products Regulatory Agency.
It becomes the seventh COVID-19 vaccine authorised by the British regulator, following expert advice from the independent Commission on Human Medicines.
VidPrevtyn Beta combines the spike protein from a COVID virus variant, Beta, with an 'adjuvant' - an additional ingredient to trigger a stronger immune response.
The clinical evidence for this authorisation is based on data from about 800 individuals previously immunised with an mRNA or viral-vectored vaccine.
The authorisation is for the use of this vaccine in those aged 18 and older, as a heterologous booster dose, given as a single injection.
This means that those who got a different vaccine (mRNA or viral-vectored) as a primary course, can receive this vaccine as a booster.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jan 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jan 23
